Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022

Written by Andreas Villaester on 1st June 2022. Posted in Client News.

• Previous
• Next